Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3745 in Glycogen Storage Disease Type 1a
NCT05095727Phase 2Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Jun 2022
- Primary completion
- Nov 2026
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 6
01
Overview
A Phase 2 trial of mRNA-3745 in glycogen storage disease type 1a (GSD1a), sponsored by Moderna Inc. Started Jun 2022; status: active, not recruiting.
02
Drugs
mRNA-3745
03
Conditions
glycogen storage disease type 1a (GSD1a)
Beyond the preview
Go deeper on NCT05095727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095727.